Clinical Trials Logo

Myocardial Ischemia clinical trials

View clinical trials related to Myocardial Ischemia.

Filter by:

NCT ID: NCT04842838 Not yet recruiting - Clinical trials for Coronary Artery Disease

Comparative Clinical Study of Drug-coating Balloon Strategy and Drug-eluting Stent Strategy

Kissing-DCB
Start date: June 30, 2021
Phase: N/A
Study type: Interventional

The trial aims to evaluate the long-term clinical outcome of the DCB-only technique is non-inferior to the provisional T stenting with DES in the patients who have 'true' bifurcation lesions.

NCT ID: NCT04837846 Recruiting - Clinical trials for Coronary Artery Disease

Multicenter Study Into Individualized Scanning for Coronary Artery Disease

MINDS-CAD
Start date: March 29, 2021
Phase:
Study type: Observational

To evaluate intravascular attenuation of the coronary arteries and image quality in an individualized scan and CM injection protocol whereas both scan and injection parameters are tailored to the individual patient in a North American, European and Asian patient population. To evaluate the radiation dose and contrast media dose of this individualized approach for CCTA in an American, European and Chinese patient population. To evaluate the injection parameters required for an average American, European and Chinese patient population.

NCT ID: NCT04835467 Not yet recruiting - Atherosclerosis Clinical Trials

First-In-Human Intracoronary OCT-FLIm In Patients Undergoing PCI

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

Patients will undergo intracoronary imaging using combined optical coherence tomography-fluorescence lifetime imaging (OCT-FLIm) during percutaneous coronary intervention, and the obtained imaging data will be used to assess the efficacy of this dual-modal catheter imaging strategy in characterizing high-risk plaque.

NCT ID: NCT04834843 Completed - Clinical trials for Coronary Artery Disease

Temporal Trends of COronary Artery Disease and PEripheral Artery Disease (COPE) in Korea

COPE registry
Start date: January 1, 2009
Phase:
Study type: Observational

Cardiovascular disease (CVD) is caused by atherosclerosis of the artery and is classified into coronary artery disease, cerebrovascular disease, and peripheral arterial disease, depending on the location of the artery and the target organs. However, since CVD share a similar pathophysiology and the probability of incidence of other CVD in CVD patients is very high. It is thought that CVD incidence and mortality can be reduced by predicting the degree of incidence of other CVD in CVD patients. The aim of this study is to investigate the incidence and mortality of other CVD diseases in CVD patients.

NCT ID: NCT04828590 Recruiting - Clinical trials for Coronary Artery Disease

The ADAPT Study: Assessment of the DiAgnostic Performance of DeepVessel FFR in SuspecTed Coronary Artery Disease

ADAPT
Start date: August 10, 2020
Phase:
Study type: Observational

DEEPVESSEL FFR is a medical device that is designed to extract three- dimensional coronary tree structures and generate computed tomography-derived fraction flow reserve (FFR) values from coronary CT angiogram images. The primary objective of this multi-center clinical validation study is to validate the clinical performance of DEEPVESSEL FFR in identifying patients with myocardial ischemia due to significant obstructive coronary artery diseases.

NCT ID: NCT04827498 Recruiting - Myocardial Ischemia Clinical Trials

Myocardial Ischemia Without Obstructive Coronary Stenoses

Start date: November 8, 2017
Phase:
Study type: Observational

Coronary-related myocardial ischemia can result from obstructive epicardial stenosis or non-obstructive causes including coronary microcirculatory dysfunction and vasomotor disorders. This prospective study has been created in order to provide knowledge in the field of non-obstructive coronary artery disease.

NCT ID: NCT04827316 Active, not recruiting - Clinical trials for Coronary Artery Disease

Clinical Utility and Outcome Prediction of Cardiovascular Computed Tomography (PREDICT-CT)

PREDICT-CT
Start date: June 1, 2017
Phase:
Study type: Observational [Patient Registry]

In this study the investigators retrospectively and prospectively collect information from enrolled subjects undergoing CCTA and evaluate the association of cardiac and non-cardiac imaging with laboratory markers and clinical data including outcome.

NCT ID: NCT04827251 Recruiting - Clinical trials for Coronary Artery Disease

Effects of Espresso on Platelet Aggregability in Patients With Coronary Artery Disease

Start date: March 18, 2019
Phase: N/A
Study type: Interventional

Discovered thousands of years ago, coffee is among the most consumed beverages in the world. The relationship between coffee and cardiovascular risk, more specifically coronary artery disease, is controversial. Platelet aggregation and its relationship with coffee is also controversial. The investigators propose this study to evaluate the relationship between coffee and platelet aggregability in patients with coronary artery disease.

NCT ID: NCT04826497 Not yet recruiting - Clinical trials for Coronary Heart Disease

Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction

Start date: April 2021
Phase: Phase 4
Study type: Interventional

The investigators evaluate the effects of intracoronary and intravenous administration of nicorandil on cardiac sympathetic nerve activity and distribution in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

NCT ID: NCT04826354 Not yet recruiting - Clinical trials for Atheroscleroses, Coronary

Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease

Start date: April 2021
Phase: Phase 4
Study type: Interventional

High-dose statins can reduce mortality and cardiovascular events in patients with established atherosclerotic cardiovascular disease (ASCVD). Therefore, US and European recommendations recommend that established ASCVD patients (coronary artery disease, cerebrovascular disease, peripheral vascular disease) use high-dose statins to lower LDL cholesterol levels by at least 50%. However, in actual practice, high-dose statins are relatively less used, and the reason is unclear, but it is believed to be due to concerns about the side effects of high-dose statins. Most of the side effects of statins are statin-associated muscle symptoms (SAMS), which are more common than the incidence in clinical studies, especially in frontline care. These muscle side effects are dose-dependent and are common at high doses, and the incidence is known to increase in the elderly over 70 years of age. However, the US recommendation recommends using high-dose statins to lower LDL cholesterol by 50% or more to prevent cardiovascular events even in ASCVD patients over 70 years of age. Most early studies on lowering LDL cholesterol in ASCVD patients used high doses of statins. However, after introducing cholesterol absorption inhibitors ezetimibe and PCSK9 inhibitor, large-scale clinical studies have been conducted to lower LDL cholesterol using these drugs. In this study, as in the statin study, cardiovascular events were significantly reduced, and together with statins, it became a standard treatment for ASCVD patients. On the other hand, the clinical benefit shown in clinical studies using cholesterol-lowering agents so far depends entirely on how much LDL cholesterol is lowered and how long it is maintained in a low state, indicating that LDL cholesterol management is the core of arteriosclerosis treatment. In addition to high-dose statins, a combination of low-dose statins and ezetimibe can be cited as a method for lowering LDL cholesterol to more than 50%. In the latter case, it is expected that there will be an advantage of reducing muscle side effects by reaching the target LDL cholesterol level by using a low-dose statin. However, no studies compare the difference in muscle side effects between low-dose statins and ezetimibe combination drugs, which reduce LDL cholesterol to the same extent compared to high-dose statins, in elderly patients over 70 years of age with ASCVD. In this study, the association of low-dose rosuvastatin 5mg and ezetimibe combination (rosuvastatin 10/5mg) compared to high-dose rosuvastatin 20mg in elderly patients 70 years of age or older with established ASCVD. This study aims to compare and analyze the incidence of muscle symptoms (SAMS) and their effect on LDL cholesterol.